Edwards Lifesciences outlines 8%–10% sales growth and $2.90–$3.05 EPS guidance for 2026 while advancing SAPIEN and TMTT platforms (NYSE:EW)
EdwardsEdwards(US:EW) Seeking Alpha·2026-02-11 00:55

Group 1 - The article does not provide any relevant content regarding company or industry insights [1]

Edwards Lifesciences outlines 8%–10% sales growth and $2.90–$3.05 EPS guidance for 2026 while advancing SAPIEN and TMTT platforms (NYSE:EW) - Reportify